BioCentury
ARTICLE | Clinical News

Intranasal sumatriptan powder: Additional Phase IIIb data

July 27, 2015 7:00 AM UTC

Additional data from the double-blind, double-dummy, crossover, U.S. Phase IIIb COMPASS trial in 275 patients with acute migraine with or without aura showed that 22 mg intranasal AVP-825 improved the...